Evidence map›Paper›PMID 39840308›Full record

ArticleIranian journal of medical sciences2024

The Correlation of Serum Adropin with Cardiovascular Risk Factors in the Experimental Rat Model of Chronic Kidney Disease and Its Implication in the Ameliorative Effect of Angiotensin-Converting Enzyme Inhibitors.

Samaa Salah Abd-El-Fatah, Maha A Fathy, Mohamed Ali Alabiad, Raja Aljafil, Mai Ahmed Gobran, Enssaf A Ahmad, Ashwag S Alsharidah, Mohammed Alorini, Sulaiman Mohammed Alnasser, Sara A Awadh and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Iranian journal of medical sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Samaa Salah Abd-El-FatahDepartment of Anatomy and Embryology, College of Medicine, Zagazig University, Al-Sharquia, Egypt.
Maha A FathyDepartment of Medical Physiology, College of Medicine, Zagazig University, Al-Sharquia, Egypt.
Mohamed Ali AlabiadDepartment of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Raja AljafilDepartment of Pathology, Faculty of Medicine, University of Benghazi, Benghazi, Libya.
Mai Ahmed GobranDepartment of Pathology, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Enssaf A AhmadDepartment of Anatomy and Embryology, College of Medicine, Zagazig University, Al-Sharquia, Egypt.
Ashwag S AlsharidahDepartment of Physiology, College of Medicine, Qassim University, Buraidah, Saudi Arabia.
Mohammed AloriniDepartment of Pathology, College of Medicine, Qassim University, Unaizah, Kingdom of Saudi Arabia.
Sulaiman Mohammed AlnasserDepartment of Pharmacology and Toxicology, College of Pharmacy, Qassim University, Qassim, Saudi Arabia.
Sara A AwadhDepartment of Biochemistry, College of Science and Art, King Abdelaziz University, Jeddah, Kingdom of Saudi Arabia.
Enas N MorganDepartment of Medical Physiology, College of Medicine, Zagazig University, Al-Sharquia, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The risk of cardiovascular disease (CVD) in patients with chronic kidney disease (CKD) is estimated to be far greater than that in the general population. Adropin regulates endothelial function and may play a role in the pathogenesis of CVD. Angiotensin-converting enzyme inhibitor (ACEI) treatment was reported to have a protective effect on both renal and cardiovascular function. This study investigated whether adropin is associated with renal and cardiovascular outcomes after using ACEI treatment in CKD rats. Methods: In 2021, in Zagazig, Egypt, rats were assigned to: GI, control group (n=8); GII, CKD group (n=8), and GIII, CKD+captopril group (n=8), in which CKD rats received 100 mg/Kg/day captopril orally. Adropin levels, renal function, blood pressure, and various CVD risk factors were measured. Renal, cardiac, and aortic tissues were examined histologically and immunohistochemically to detect the expression of vascular endothelial growth factor receptor-2 (VEGFR-2). To analyze data, ANOVA and Pearson's correlation tests were used (SPSS version 18, P<0.05 is significant). Results: Adropin was significantly lower in GII than in GI and GIII (P<0.001). Adropin in GII and GIII was negatively correlated with atherogenic index (P=0.019 and P=0.001, respectively), atherogenic co-efficient (P=0.012 and P=0.013, respectively), troponin I (P=0.021 and P=0.043, respectively), and nitric oxide (P=0.025 and P=0.038, respectively). VEGFR-2 expression decreased in GII and was elevated in GIII (P<0.001). Conclusion: Adropin levels were significantly correlated with most CVD risk factors in CKD and captopril-treated CKD rats, indicating a role for adropin in the pathogenesis of CVD in CKD. It also refers to its implication in the ameliorative effect of ACEI treatment, possibly by affecting VEGFR-2 and nitric oxide release.

Indexed as

Angiotensin-Converting Enzyme InhibitorsCardiovascular DiseasesPeptidesRenal Insufficiency, ChronicAnimalsBlood ProteinsDisease Models, AnimalHeart Disease Risk FactorsIntercellular Signaling Peptides and ProteinsMaleRatsRisk FactorsAngiotensin-Converting Enzyme InhibitorsBlood ProteinsENHO protein, ratIntercellular Signaling Peptides and ProteinsPeptidesAdropinChronic kidney diseaseHeart disease risk factorsPeptidyl-dipeptidase ARenal insufficiency

Identifiers

PMID39840308
PMCPMC11743441

What OpenQuestion holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.